Unveiling the immunological terrain of pancreatic ductal adenocarcinoma: strategies to prompt immunotherapy from Mendelian randomization
This study enhances our understanding of PDAC's resistance to immunotherapies and highlights the potential of personalized immunotherapy and metabolic pathway modulation in PDAC treatment. Our findings provide supportive evidence for research and clinical translation.
Authors
- Yangfeng Zhang (ORCID: https://orcid.org/0000-0002-4993-2808)
- Changqian Wang (ORCID: https://orcid.org/0000-0002-7611-7761)
- Duanyu Wang
- Ying Li (ORCID: https://orcid.org/0000-0002-7651-6543)
- Chongyang Zheng (ORCID: https://orcid.org/0009-0004-5396-0029)
- Qianzi Kou
- Pengkhun Nov (ORCID: https://orcid.org/0000-0002-7016-8285)
- Peizan Ni (ORCID: https://orcid.org/0000-0002-8010-1375)
- Lilin Li (ORCID: https://orcid.org/0000-0001-7559-1018)
- Jiqiang Li (ORCID: https://orcid.org/0000-0002-0962-9118)
- Wen Fu (ORCID: https://orcid.org/0000-0003-2646-0577)
- Kunpeng Du (ORCID: https://orcid.org/0000-0002-6462-4598)
Institutions
- Zhujiang Hospital (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-04-25
- DOI
- https://doi.org/10.1007/s12672-025-02250-7
- Citations
- 2
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- National Natural Science Foundation of China